MedPath

Stapler vs. LigaSure in Elective Hepatic Resection

Not Applicable
Completed
Conditions
Liver Resection
Interventions
Procedure: Stapler hepatectomy
Procedure: LigaSure hepatectomy
Other: vascular staple
Device: Ligasure
Registration Number
NCT01858987
Lead Sponsor
Heidelberg University
Brief Summary

The optimal technique of parenchymal transection in liver surgery has remained a matter of controversial debate among hepatobiliary surgeons. The optimal technique should enable secure sealing of the vascular and biliary structures that results in low intraoperative blood loss as well as low postoperative complication rates. Although numerous devices have been introduced and are used widely, high-level evidence, randomized controlled trials, that evaluate efficacy and safety of these devices are scarce. In the present randomized controlled trial two techniques of hepatic resection using vascular staplers and the LigaSure vessel sealing device are compared. While the primary endpoint is intraoperative blood loss a set of general and surgical variables will be analyzed to evaluate efficacy and safety of both methods.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
138
Inclusion Criteria
  • Patients scheduled for elective hepatic resection
  • Parenchymal transection by vascular stapler and LigaSure feasible
  • Age equal or greater than 18 years
  • Informed consent
Exclusion Criteria
  • Extrahepatic resection required based on preoperative imaging
  • Participation in concurrent surgical intervention trials
  • Expected lack of compliance
  • Impaired mental state or language problems

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Stapler hepatectomyStapler hepatectomyLiver resection using vascular stapler for transection of the parenchyma
LigaSure HepatectomyLigaSure hepatectomyLiver resection using LigaSure for transection of the parenchyma
Stapler hepatectomyvascular stapleLiver resection using vascular stapler for transection of the parenchyma
LigaSure HepatectomyLigasureLiver resection using LigaSure for transection of the parenchyma
Primary Outcome Measures
NameTimeMethod
Intraoperative Blood lossBeginning to end of surgical procedure

Intraoperative blood loss represents the primary efficacy endpoint of the CRUNSH II-Trial. To obtain a more precise estimate for the individual patient patient's individual transection area will be considered as a continuous covariate in the analysis of covariance (ANOVA). The transection area will be assessed using an imprint of the resected specimen on a paper sheet with a known density of 80 mg/m2. The marked paper area will be cut and weight to calculate the transection area. Intraoperative blood loss will be measured according to the blood collected in the suction containers. Spilling water and ascites will be subtracted. Furthermore, swabs will be squeezed and their content will also be sucked and added to the fluid collected in the suction containers. Central venous pressure will be lowered below 5 cmH2O for the transection period.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

UniversityHospital Dresden

🇩🇪

Dresden, Germany

© Copyright 2025. All Rights Reserved by MedPath